



Surbhi Sidana, MD

Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Medicine - Blood & Marrow Transplantation

CLINICAL OFFICE (PRIMARY)

- **Blood and Marrow Transplantation**

875 Blake Wilbur Dr Clinic C

MC 5820

Stanford, CA 94305

Tel (650) 498-6000

Fax (650) 725-3321

Bio

BIO

Dr. Sidana is a hematologist/oncologist who is fellowship trained in advanced hematology with an emphasis on myeloma, amyloidosis, and dysproteinemia disorders. She is an Assistant Professor in the Department of Medicine, Division of Blood and Marrow Transplantation & Cellular Therapy, at Stanford University School of Medicine. She leads the Myeloma Cellular Immunotherapy program at Stanford.

Her areas of expertise include transplantation and novel cellular immunotherapies such as CAR-T-cell therapy for patients with multiple myeloma. For each patient, Dr. Sidana develops a personalized care plan designed to optimize outcomes and quality of life.

Dr. Sidana conducts extensive research. Currently, she is conducting clinical trials of CAR-T therapy and bispecific T-cell engagers for treatment of patients with myeloma. She is studying patients' access to CAR-T cell therapy, the financial burden of the treatment, and its impact on patients' quality of life and cognitive function.

Dr Sidana has received a grant from the Stanford Medicine Cancer Institute and NIH funding through the Stanford KL2 program to study adverse events of CAR-T therapy on patients and monitoring of patients undergoing CAR-T therapy using wearable devices.

In the past, Dr. Sidana received Conquer Cancer Foundation Young Investigator Award from the American Society of Clinical Oncology for her research on the impact of clinical trial participation on patients with multiple myeloma and lymphoma. She has also received grants from the Amyloidosis Foundation and International Waldenström's Macroglobulinemia Foundation to understand AL amyloidosis, a rare disease caused by buildup of an abnormal protein.

Dr. Sidana has given presentations at regional and national conferences and her work has been published in high-impact journals.

Dr. Sidana has been recognized for her work with many honors, including an Outstanding Hematology/Oncology Fellow award and Outstanding Research Fellow award from the Mayo Clinic.

She is a member of the American Society of Hematology, American Society of Clinical Oncology, International Myeloma Society, International Society of Amyloidosis, and American Society of Transplantation & Cellular Therapy. Dr. Sidana is often an invited speaker at patient support groups as well as symposia and workshops for her peers.

CLINICAL FOCUS

- Multiple Myeloma
- Amyloidosis
- POEMS Syndrome
- Waldenstrom's Macroglobulinemia
- Cryoglobulinemia
- CAR-T Cell Therapy
- Hematopoietic Stem Cell Transplantation
- Hematology

ACADEMIC APPOINTMENTS

- Assistant Professor - University Medical Line, Medicine - Blood & Marrow Transplantation
- Member, Bio-X
- Member, Stanford Cancer Institute

HONORS AND AWARDS

- Merit Award, American Society of Clinical Oncology/Conquer Cancer Foundation (2019)
- Hematology/Oncology Outstanding Fellow, Mayo Clinic, Rochester, MN (2018)
- Junior Researcher Travel Award, Amyloidosis Foundation (2018)
- Outstanding Research Fellow, Department of Medicine, Mayo Clinic, Rochester, MN (2018)
- Research Grant for Early Career Investigators, Amyloidosis Foundation (2018)
- Young Investigator Award, 10th International Workshop on Waldenstrom's Macroglobulinemia (2018)
- "NextGen Innovator", HemOnc Today (2017)
- Clinical Research Training Institute, American Society of Hematology (2017)
- Merit Award, American Society of Clinical Oncology/Conquer Cancer Foundation (2017)
- Outstanding Fellow Award, Minnesota Society of Clinical Oncology (2017)
- Research Grant (Co-Principal Investigator), International Waldenstrom's Macroglobulinemia Foundation (2017)
- Young Investigator Award, American Society of Clinical Oncology/Conquer Cancer Foundation (2017)
- Abstract Achievement Award, American Society of Hematology (2016)
- Methods in Clinical Cancer Research Workshop, Vail, CO, American Association of Cancer Research/American Society of Clinical Oncology (2016)
- Gold Medal, best academic performance in Internal Medicine, Maulana Azad Medical College, University of Delhi (2010)
- Lt. Governor's Rolling Trophy - Best student in medical school graduating class, Maulana Azad Medical College, University of Delhi (2010)
- Dean's Roll of Honor for best academic performance, Maulana Azad Medical College, University of Delhi (2008)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, Biomarkers Committee, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) (2020 - present)
- Member, Editor Search Committee, American Society of Hematology (2019 - present)
- Co-Chair, Taskforce on trainees and junior faculty, American Society of Transplantation and Cellular Therapy (2019 - present)

- Member, Protocol Writing Committee, BMT CTN 1901/1902, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) (2019 - present)
- Member, Professional Development Committee, American Society of Clinical Oncology (2018 - 2019)
- Member, Chair 2018-19 term, Trainee and Early Career Council, American Society of Clinical Oncology (2017 - present)
- Member, Trainee Council and Liaison to Communications Committee, American Society of Hematology (2017 - 2019)
- Member, European Hematology Association (2019 - present)
- Member, International Society of Amyloidosis (2017 - present)
- Member, International Myeloma Society (2016 - present)

PROFESSIONAL EDUCATION

- Fellowship, Mayo Clinic, Rochester, MN , Myeloma, Amyloidosis and Related Disorders (Advanced Hematology)
- Fellowship, Mayo Clinic, Rochester, MN , Hematology and Oncology
- Residency, Cleveland Clinic, OH , Internal Medicine
- Medical Education, Maulana Azad Medical College, University of Delhi, India

Research & Scholarship

CLINICAL TRIALS

- Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release, Recruiting
- A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel, Not Recruiting
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PvD) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma, Not Recruiting
- A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma, Not Recruiting
- A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma, Not Recruiting
- A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DvD) in Participants With Relapsed or Refractory Multiple Myeloma, Not Recruiting
- A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma, Not Recruiting
- Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies, Not Recruiting
- CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies, Not Recruiting
- MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma, Not Recruiting
- MM CAR-T to Upgrade Response BMTCTN1902, Not Recruiting
- PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma, Not Recruiting
- Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma, Not Recruiting
- Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL), Not Recruiting

Publications

PUBLICATIONS

- **Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma.** *Blood cancer journal* Sidana, S., Hosoya, H., Jensen, A., Liu, L., Goyal, A., Hovanky, V., Sahaf, B., Bharadwaj, S., Latchford, T., Arai, S., Leahy, S., Mei, M., Budde, et al 2023; 13 (1): 158
- **Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.** *Haematologica* Sidana, S., Peres, L. C., Hashmi, H., Hosoya, H., Ferreri, C., Khouri, J., Dima, D., Atrash, S., Voorhees, P., Simmons, G., Sborov, D. W., Kalariya, N., Hovanky, et al

2023

- **Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.** *Blood cancer journal*
Ferreri, C. J., Hildebrandt, M. A., Hashmi, H., Shune, L. O., McGuirk, J. P., Sborov, D. W., Wagner, C. B., Kocoglu, M. H., Rapoport, A., Atrash, S., Voorhees, P. M., Khouri, J., Dima, et al
2023; 13 (1): 117
- **First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PvD or DPd) in lenalidomide-refractory multiple myeloma.**
Dhakal, B., Yong, K., Harrison, S. J., Mateos, M., Moreau, P., van de Donk, N. J., Sidana, S., Popat, R., Lendvai, N., Lonardi, C., Slaughter, A., Schecter, J., Li, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.** *The New England journal of medicine*
San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M. V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., Leleu, X., Avivi, I., Cavo, et al
2023
- **Embracing Myeloma Chimeric Antigen Receptor-T: From Scientific Design to Clinical Impact.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*
Hosoya, H., Rodríguez-Otero, P., Sidana, S., Borrello, I. M.
2023; 43: e389860
- **Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).**
van de Donk, N. J., Moreau, P., Garfall, A. L., Bhutani, M., Oriol, A., Nooka, A. K., Martin, T. G., Rosinol, L., Mateos, M., Bahlis, N. J., Popat, R., Besemer, B., Martinez-Lopez, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world experience from the US myeloma CAR T consortium.**
Afrough, A., Hashmi, H., Hansen, D. K., Sidana, S., Ahn, C., Dima, D., Freeman, C. L., Puglianini, O., Kocoglu, M. H., Atrash, S., Voorhees, P. M., Shune, L., Simmons, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucl (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM).**
Hansen, D. K., Patel, K. K., Peres, L. C., Kocoglu, M. H., Shune, L., Simmons, G., Ferreri, C. J., Atrash, S., Parrondo, R., Chhabra, S., Costello, P., Midha, S., Alsina, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Reply to R. Chakraborty et al.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Hansen, D. K., Sidana, S., Peres, L. C., Patel, K. K.
2023: JCO2300568
- **Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma.** *Future oncology (London, England)*
Moreau, P., van de Donk, N. W., Nahi, H., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Karlin, L., Benboubker, L., Mateos, M., Popat, R., Martinez-Lopez, J., Sidana, et al
2023
- **Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.** *Cancer*
Bumma, N., Dhakal, B., Fraser, R., Estrada-Merly, N., Anderson, K., Freytes, C. O., Hildebrandt, G. C., Holmberg, L., Krem, M. M., Lee, C., Lekakis, L., Lazarus, H. M., Mian, et al
2023
- **Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.** *Nature medicine*
Mailankody, S., Matous, J. V., Chhabra, S., Liedtke, M., Sidana, S., Oluwole, O. O., Malik, S., Nath, R., Anwer, F., Cruz, J. C., Htut, M., Karski, E. E., Lovelace, et al
2023
- **Ethical challenges with multiple myeloma BCMA CAR-T slot allocation: a multi-institution experience.** *Transplantation and cellular therapy*
Kourelis, T., Bansal, R., Berdeja, J., Siegel, D., Patel, K., Mailankody, S., Htut, M., Shah, N., Wong, S. W., Sidana, S., Cowan, A. J., Alsina, M., Cohen, et al
2023

- **Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Hansen, D. K., Sidana, S., Peres, L. C., Colin Leitzinger, C., Shune, L., Shrewsbury, A., Gonzalez, R., Sborov, D. W., Wagner, C., Dima, D., Hashmi, H., Kocoglu, M. H., Atrash, et al
2023: JCO2201365
- **Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis.** *ClinicoEconomics and outcomes research : CEOR*
Gertz, M., Abonour, R., Gibbs, S. N., Finkel, M., Landau, H., Lentzsch, S., Lin, G., Mahindra, A., Quock, T., Rosenbaum, C., Rosenzweig, M., Sidana, S., Tuchman, et al
2023; 15: 673-680
- **Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA**
Hosoya, H., Carleton, M., Tanaka, K. L., Sworder, B., Hovanky, V., Duran, G. E., Zhang, T. Y., Khodadoust, M. S., Miklos, D. B., Arai, S., Iberri, D., Liedtke, M., Sidana, et al
AMER SOC HEMATOLOGY.2022: 1546-1548
- **Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma CAR T Consortium Real World Experience**
Khouri, J., Li, H., Hansen, D. K., Sidana, S., Shune, L. O., DeJarnette, S., Anwer, F., Sborov, D. W., Wagner, C. B., Kocoglu, M., Atrash, S., Voorhees, P. M., Valent, et al
AMER SOC HEMATOLOGY.2022: 10427-10429
- **Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects**
Hamilton, M. P., Liu-Fei, F. C., Alig, S. K., Tamaresis, J., Esfahani, M., Good, Z., Sworder, B., Schroers-Martin, J., Liu, C., Severinsen, F., Hanson, P. J., Lu, Y., Lowsky, et al
AMER SOC HEMATOLOGY.2022: 7545-7547
- **Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref NonHodgkin Lymphoma**
Bharadwaj, S., Hamilton, M. P., Sahaf, B., Tamaresis, J., Patil, S., Hanson, P. J., Latchford, T., Arai, S., Johnston, L. J., Lowsky, R., Negrin, R. S., Rezvani, A. R., Shizuru, et al
AMER SOC HEMATOLOGY.2022: 10371-10373
- **Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): US Myeloma CAR T Consortium Real World Experience**
Hashmi, H., Hansen, D. K., Peres, L. C., Puglianini, O., Freeman, C. L., De Avila, G., Sidana, S., Shune, L. O., Sborov, D. W., Davis, J., Wagner, C. B., Kocoglu, M., Atrash, et al
AMER SOC HEMATOLOGY.2022: 4642-4645
- **Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy**
Peres, L. C., Oswald, L. B., Dillard, C., De Avila, G., Nishihori, T., Blue, B. J., Freeman, C. L., Locke, F. L., Alsina, M., Puglianini, O., Shune, L. O., Sborov, D. W., Wagner, et al
AMER SOC HEMATOLOGY.2022
- **Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma**
Mailankody, S., Matous, J., Liedtke, M., Sidana, S., Oluwole, O. O., Mohan, M., Cruz, J. C., Nath, R., Anwer, F., Rossi, A., Htut, M., Malik, S. A., Ghatta, et al
AMER SOC HEMATOLOGY.2022: 4620-4622
- **Early cytopenias and infections after standard of care icleucel#in relapsed or refractory multiple myeloma.** *Blood advances*
Logue, J. M., Peres, L. C., Hashmi, H., Colin-Leitzinger, C., Shrewsbury, A. M., Hosoya, H., Gonzalez, R., Copponex, C., Kottra, K. H., Hovanky, V., Sahaf, B., Patil, S., Lazaryan, et al
2022
- **Teclistamab in Relapsed or Refractory Multiple Myeloma.** *The New England journal of medicine*
Moreau, P., Garfall, A. L., van de Donk, N. W., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., Karlin, L., Benboubker, L., Mateos, et al
2022
- **Ethical challenges with CAR T slot allocation with icleucel manufacturing access.**
Kourelis, T., Bansal, R., Patel, K. K., Berdeja, J. G., Raje, N. S., Alsina, M., Cohen, A. D., Siegel, D., Mailankody, S., Htut, M., Sidana, S., Holstein, S. A., Cowan, et al

LIPPINCOTT WILLIAMS & WILKINS.2022

- **Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience.**
Hansen, D. K., Sidana, S., Peres, L., Shune, L., Sborov, D. W., Hashmi, H., Kocoglu, M. H., Atrash, S., Simmons, G., Kalariya, N., Ferreri, C. J., Afrough, A., Kansagra, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care.** *JCO oncology practice*
Sidana, S., Allmer, C., Larson, M. C., Dueck, A., Yost, K., Warsame, R., Thanarajasingam, G., Cerhan, J. R., Paludo, J., Rajkumar, S. V., Habermann, T. M., Nowakowski, G. S., Lin, et al
2022: OP2100789
- **Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era.** *Transplantation and cellular therapy*
Liang, E. C., Craig, J., Torelli, S., Cunanan, K., Iglesias, M., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., Negrin, R., Rezvani, et al
2022
- **Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy vs Autologous and Allogeneic Stem Cell Transplant.** *Transplantation and cellular therapy*
Sidana, S., Dueck, A. C., Thanarajasingam, G., Griffin, J. M., Thompson, C., Durani, U., Burtis, M., Warsame, R., Paludo, J., Gertz, M. A., Dispenzieri, A., Ansell, S. M., Rajkumar, et al
2022
- **Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.** *The Lancet. Haematology*
Thanarajasingam, G., Minasian, L. M., Bhatnagar, V., Cavalli, F., De Claro, R. A., Dueck, A. C., El-Galaly, T. C., Everest, N., Geissler, J., Gisselbrecht, C., Gormley, N., Gribben, J., Horowitz, et al
2022; 9 (5): e374-e384
- **Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies** *LANCET HAEMATOLOGY*
Thanarajasingam, G., Minasian, L. M., Bhatnagar, V., Cavalli, F., De Claro, R., Dueck, A. C., El-Galaly, T. C., Everest, N., Geissler, J., Gisselbrecht, C., Gormley, N., Gribben, J., Horowitz, et al
2022; 9 (5): E374-E384
- **Updated Results From the Phase 1/2 MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma**
Popat, R., Usmani, S. Z., Garfall, A., van de Donk, N., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A., Martin, T., Rosinol, L., Chari, A., Karlin, L., Benboubker, et al
WILEY.2022: 35-36
- **Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report.** *Transplantation and cellular therapy*
Bankova, A. K., Caveney, J., Yao, B., Ramos, T. L., Bogeholz, J., Heydari, K., Diaz, N., Jackson, M. L., Lowsky, R., Brown, J. W., Johnston, L., Rezvani, A. R., Frank, et al
1800
- **Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma.** *Blood advances*
Kansagra, A., Dispenzieri, A., Fraser, R., Estrada-Merly, N., Sidana, S., Nishihori, T., Hansen, D. K., Anderson, L. D., Banerjee, R., Bumma, N., Dhakal, B., Khouri, J., Landau, et al
2022
- **Mgta-145+Plerixafor Provides GCSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study**
Sidana, S., Bankova, A. K., Hosoya, H., Kumar, S., Tamaresis, J., Le, A., Muffly, L., Johnston, L. J., Arai, S., Lowsky, R., Meyer, E. H., Rezvani, A. R., Weng, et al
AMER SOC HEMATOLOGY.2021
- **Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma**
Moreau, P., Usmani, S. Z., Garfall, A. L., van de Donk, N. J., Nahi, H., San-Miguel, J., Oriol, A., Nooka, A. K., Martin, T., Rosino, L., Chari, A., Karlin, L., Benboubker, et al

AMER SOC HEMATOLOGY.2021

- **Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma**
Mailankody, S., Liedtke, M., Sidana, S., Matous, J. V., Chhabra, S., Oluwole, O. O., Malik, S. A., Kumar, S., Nath, R., Anwer, F., Cruz, J., Jagannath, S., Httu, et al
AMER SOC HEMATOLOGY.2021
- **Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal Study**
Cusatis, R., Tan, I., Piehowski, C., Akinola, I., Crawford, E., Craig, J., Thiengmany, A., Frank, M. J., Miklos, D. B., Shah, N. N., D'Souza, A., Knight, J. M., Muffly, et al
AMER SOC HEMATOLOGY.2021
- **Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy** *BLOOD ADVANCES*
Johnsrud, A., Craig, J., Baird, J., Spiegel, J., Muffly, L., Zehnder, J., Tamaresis, J., Negrin, R., Johnston, L., Arai, S., Shizuru, J., Lowsky, R., Meyer, et al
2021; 5 (21): 4465-4475
- **Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.** *Blood advances*
Muffly, L., Sundaram, V., Chen, C., Yurkiewicz, I., Kuo, E., Burnash, S., Spiegel, J. Y., Arai, S., Frank, M. J., Johnston, L. J., Lowsky, R., Meyer, E. H., Negrin, et al
2021; 5 (16): 3147-3151
- **CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.** *Nature medicine*
Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., Frank, M. J., Shiraz, P., Sahaf, B., Craig, J., Iglesias, M., Younes, S., Natkunam, et al
2021
- **Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.** *Bone marrow transplantation*
Lemieux, C., Muffly, L. S., Iberri, D. J., Craig, J. K., Johnston, L. J., Lowsky, R., Shiraz, P., Rezvani, A. R., Frank, M. J., Weng, W., Meyer, E., Shizuru, J. A., Arai, et al
2021
- **Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report**
Bankova, A., Caveney, J., Ramos, T., Bogeholz, J., Heydari, K., Diaz, N., Jackson, M., Lowsky, R., Brown, J., Johnston, L., Rezvani, A., Frank, M., Muffly, et al
SPRINGERNATURE.2021: 181
- **Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma.**
Sidana, S., Bankova, A., Hosoya, H., Muffly, L. S., Kumar, S., Johnston, L. J., Lowsky, R., Meyer, E., Rezvani, A., Weng, W., Arai, S., Frank, M., Shiraz, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis.** *Blood advances*
Sidana, S., Dasari, S., Kourelis, T. V., Dispenzieri, A., Murray, D. L., King, R. L., McPhail, E. D., Ramirez-Alvarado, M., Kumar, S. K., Gertz, M. A.
2021; 5 (8): 2101-5
- **Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era.** *Transplantation and cellular therapy*
Johnsrud, A., Ladha, A., Muffly, L., Shiraz, P., Goldstein, G., Osgood, V., Shizuru, J. A., Johnston, L., Arai, S., Weng, W., Lowsky, R., Rezvani, A. R., Meyer, et al
2021
- **Antibody-Based Treatment Approaches in Multiple Myeloma.** *Current hematologic malignancy reports*
Hosoya, H., Sidana, S.
2021
- **Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group** *LANCET ONCOLOGY*
Moreau, P., Kumar, S. K., Miguel, J., Davies, F., Zamagni, E., Bahls, N., Ludwig, H., Mikhael, J., Terpos, E., Schjesvold, F., Martin, T., Yong, K., Durie, et al
2021; 22 (3): E105-E118
- **Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.** *Transplantation and cellular therapy*
Liang, E. C., Muffly, L. S., Shiraz, P., Shizuru, J. A., Johnston, L., Arai, S., Frank, M. J., Weng, W., Lowsky, R., Rezvani, A., Meyer, E. H., Negrin, R., Miklos, et al
2021

- **Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma** *BLOOD ADVANCES*
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., Claire, G. K., Frank, M. J., Muffly, L., Shiraz, P., Meyer, E., Arai, S., Brown, et al
2021; 5 (1): 143–55
- **Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort.** *American journal of hematology*
Drosou, M. E., Vaughan, L. E., Muchtar, E. n., Buadi, F. K., Dingli, D. n., Dispenzieri, A. n., Fonder, A. L., Gertz, M. A., Go, R. S., Gonsalves, W. I., Hayman, S. R., Hobbs, M. A., Hwa, et al
2021
- **Title: Impact of Induction Therapy with VRD vs. VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.** *Transplantation and cellular therapy*
Sidana, S., Kumar, S., Fraser, R., Estrada-Merly, N., Giralt, S., Agrawal, V., Anderson, L. D., Aljurf, M., Banerjee, R., Bashey, A., Battiwalla, M., Beitinjaneh, A., Chakraborty, et al
2021
- **Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy.** *Blood advances*
Johnsrud, A. J., Craig, J., Baird, J. H., Spiegel, J. Y., Muffly, L., Zehnder, J. L., Tamaresis, J. S., Negrin, R. S., Johnston, L., Arai, S., Shizuru, J. A., Lowsky, R., Meyer, et al
2021
- **Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.** *The Lancet. Oncology*
Moreau, P. n., Kumar, S. K., San Miguel, J. n., Davies, F. n., Zamagni, E. n., Bahlis, N. n., Ludwig, H. n., Mikhael, J. n., Terpos, E. n., Schjesvold, F. n., Martin, T. n., Yong, K. n., Durie, et al
2021; 22 (3): e105–e118
- **Outcomes with different administration schedules of Bortezomib in Bortezomib, Lenalidomide and dexamethasone (VRd) as first-line therapy in Multiple Myeloma.** *American journal of hematology*
Cook, J., Johnson, I., Higgins, A., Sidana, S., Warsame, R., Gonsalves, W., Gertz, M. A., Buadi, F., Lacy, M., Kapoor, P., Dispenzieri, A., Kourelis, T., Dingli, et al
2020
- **Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
Lemieux, C., Johnston, L. J., Lowsky, R., Muffly, L. S., Craig, J. K., Shiraz, P., Rezvani, A., Frank, M. J., Weng, W., Meyer, E., Shizuru, J., Arai, S., Negrin, et al
2020
- **International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.** *Leukemia*
Costa, L. J., Derman, B. A., Bal, S., Sidana, S., Chhabra, S., Silbermann, R., Ye, J. C., Cook, G., Cornell, R. F., Holstein, S. A., Shi, Q., Omel, J., Callander, et al
2020
- **Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis.** *Bone marrow transplantation*
Abdallah, N., Sidana, S., Dispenzieri, A., Lacy, M., Buadi, F., Hayman, S., Kapoor, P., Leung, N., Dingli, D., Hwa, Y. L., Lust, J., Russell, S., Gonsalves, et al
2020
- **Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).**
Tam, E., Iberri, D., Liedtke, M., Muffly, L. S., Shiraz, P., Frank, M., Lowsky, R., Rezvani, A., Negrin, R., Meyer, E., Arai, S., Johnston, L. J., Shizuru, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Quality of life (QOL), financial burden, and perception of care in patients enrolled on clinical trials (CTs).**
Sidana, S., Allmer, C., Larson, M. C., Dueck, A. C., Yost, K. J., Warsame, R. M., Thanarajasingam, G., Cerhan, J., Paludo, J., Rajkumar, S., Habermann, T., Nowakowski, G. S., Lin, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Glycosylation of Immunoglobulin Light Chains is Highly Prevalent in Cold Agglutinin Disease.** *American journal of hematology*
Sidana, S., Murray, D. L., Dasari, S., Go, R. S., Muchtar, E., Willrich, M. A., Snyder, M., Kohlhagen, M., Lust, J. A., Kourelis, T. V., Kumar, S. K., Dispenzieri, A., Gertz, et al
2020
- **A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis.** *Blood cancer journal*
Sidana, S., Milani, P., Binder, M., Basset, M., Tandon, N., Foli, A., Dispenzieri, A., Gertz, M. A., Hayman, S. R., Buadi, F. K., Lacy, M. Q., Kapoor, P., Leung, et al

2020; 10 (4): 41

- **Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era**
Muffly, L., Arai, S., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., Negrin, R. S., Rezvani, A., Shiraz, P., Shizuru, J. A., Sidana, S., Weng, W., Cunanan, et al
ELSEVIER SCIENCE INC.2020: S106
- **Impact of Minimal Residual Negativity using Next Generation Flow Cytometry on Outcomes in Light Chain Amyloidosis.** *American journal of hematology*
Sidana, S., Muchtar, E., Sidiqi, M. H., Jevremovic, D., Dispenzieri, A., Gonsalves, W., Buadi, F., Lacy, M. Q., Hayman, S. R., Kourelis, T., Kapoor, P., Go, R. S., Warsame, et al
2020
- **Organ responses with daratumumab therapy in previously treated AL amyloidosis.** *Blood advances*
Chung, A. n., Kaufman, G. P., Sidana, S. n., Eckhert, E. n., Schrier, S. L., Lafayette, R. A., Arai, S. n., Witteles, R. M., Liedtke, M. n.
2020; 4 (3): 458–66
- **CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.** *Blood*
Baird, J. H., Frank, M. J., Craig, J. n., Patel, S. n., Spiegel, J. Y., Sahaf, B. n., Oak, J. S., Younes, S. n., Ozawa, M. n., Yang, E. n., Natkunam, Y. n., Tamaresis, J. S., Ehlinger, et al
2020
- **Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.** *Bone marrow transplantation*
Lemieux, C. n., Muffly, L. S., Rezvani, A. n., Lowsky, R. n., Iberri, D. J., Craig, J. K., Frank, M. J., Johnston, L. J., Liedtke, M. n., Negrin, R. n., Weng, W. K., Meyer, E. n., Shizuru, et al
2020
- **Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?**
Sidana, S., Manasanch, E.
AMER SOC HEMATOLOGY.2019: 142–47
- **CAR T-cell therapy: is it prime time in myeloma?**
Sidana, S., Shah, N.
AMER SOC HEMATOLOGY.2019: 260–65
- **Revisiting complete response in light chain amyloidosis.** *Leukemia*
Sidana, S., Dispenzieri, A., Murray, D. L., Go, R. S., Buadi, F. K., Lacy, M. Q., Gonsalves, W. I., Dingli, D., Warsame, R., Kourelis, T., Muchtar, E., Hayman, S. R., Kapoor, et al
2019
- **Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis.** *Leukemia*
Muchtar, E., Gertz, M. A., Kourelis, T. V., Sidana, S., Go, R. S., Lacy, M. Q., Buadi, F. K., Dingli, D., Hayman, S. R., Kapoor, P., Leung, N., Fonder, A., Hobbs, et al
2019
- **Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis**
Chung, A., Kaufman, G. P., Sidana, S., Eckhert, E., Schrier, S., Arai, S., Lafayette, R., Witteles, R., Liedtke, M.
AMER SOC HEMATOLOGY.2019
- **Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life**
Sidana, S., Thanarajasingam, G., Griffin, J., Thompson, C. A., Burtis, M., Warsame, R., Paludo, J., Cheville, A., Gertz, M. A., Dispenzieri, A., Villasboas, J., Ansell, S. M., Rajkumar, et al
AMER SOC HEMATOLOGY.2019
- **Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease**
Sidana, S., Murray, D. L., Dasari, S., Go, R. S., Willrich, M., Snyder, M., Kohlhagen, M., Lust, J. A., Muchtar, E., Kourelis, T., Kumar, S. K., Dispenzieri, A., Gertz, et al
AMER SOC HEMATOLOGY.2019

- **Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis**
Sidana, S., Dasari, S., Kourelis, T., Dispenzieri, A., Murray, D. L., King, R. L., McPhail, E. D., Ramirez-Alvarado, M., Kumar, S. K., Gertz, M. A.
AMER SOC HEMATOLOGY.2019
- **Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep Responses**
Chung, A., Kaufman, G. P., Sidana, S., Iberri, D., Eckhert, E., Schrier, S., Lafayette, R., Arai, S., Witteles, R., Liedtke, M.
AMER SOC HEMATOLOGY.2019
- **Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis** *AMERICAN JOURNAL OF HEMATOLOGY*
Al Saleh, A. S., Sidiqi, M., Sidana, S., Muchtar, E., Dispenzieri, A., Dingli, D., Lacy, M. Q., Warsame, R. M., Gonsalves, W. I., Kourelis, T. V., Hogan, W. J., Hayman, S. R., Wolf, et al
2019; 1066–71
- **Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis** *AMERICAN JOURNAL OF HEMATOLOGY*
Sidana, S., Sidiqi, M., Dispenzieri, A., Buadi, F. K., Lacy, M. Q., Muchtar, E., Dingli, D., Haynann, S. R., Gonsalves, W., Kapoor, P., Leung, N., Warsame, R., Kourelis, et al
2019
- **Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis** *BRITISH JOURNAL OF HAEMATOLOGY*
Sidana, S., Tandon, N., Gertz, M. A., Dispenzieri, A., Ramirez-Alvarado, M., Murray, D. L., Kourelis, T. V., Buadi, F. K., Kapoor, P., Gonsalves, W., Warsame, R., Lacy, M. Q., Kyle, et al
2019; 185 (4): 701–7
- **Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
Chakraborty, R., Sidana, S., Shah, G. L., Scordo, M., Hamilton, B. K., Majhail, N. S.
2019; 25 (5): e155–e162
- **Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma** *AMERICAN JOURNAL OF HEMATOLOGY*
Sidana, S., Jevremovic, D., Ketterling, R. P., Tandon, N., Greipp, P. T., Baughn, L. B., Dispenzieri, A., Gertz, M. A., Rajkumar, S., Kumar, S. K.
2019; 94 (5): E117–E120
- **Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method** *AMERICAN JOURNAL OF HEMATOLOGY*
Sidana, S., Jevremovic, D., Ketterling, R. P., Tandon, N., Dispenzieri, A., Gertz, M. A., Greipp, P. T., Baughn, L. B., Buadi, F. K., Lacy, M. Q., Morice, W., Hanson, C., Timm, et al
2019; 94 (4): 424–30
- **Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma** *BLOOD ADVANCES*
Tandon, N., Sidana, S., Rajkumar, S., Gertz, M. A., Buadi, F. K., Lacy, M. Q., Kapoor, P., Gonsalves, W., Dispenzieri, A., Kourelis, T., Warsame, R., Dingli, D., Fonder, et al
2019; 3 (5): 744–50
- **Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis** *MAYO CLINIC PROCEEDINGS*
Sidana, S., Tandon, N., Brady, P. A., Grogan, M., Gertz, M. A., Dispenzieri, A., Lin, G., Dingli, D., Buadi, F. K., Lacy, M. Q., Kapoor, P., Gonsalves, W., Muchtar, et al
2019; 94 (3): 455–64
- **Primary systemic amyloidosis in patients with Waldenstrom macroglobulinemia** *LEUKEMIA*
Zanwar, S., Abeykoon, J. P., Ansell, S. M., Gertz, M. A., Dispenzieri, A., Muchtar, E., Sidana, S., Tandon, N., Rajkumar, S., Dingli, D., Go, R., Lacy, M. Q., Kourelis, et al
2019; 33 (3): 790–94
- **Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse** *LEUKEMIA*
Sidana, S., Tandon, N., Dispenzieri, A., Gertz, M. A., Buadi, F. K., Lacy, M. Q., Dingli, D., Fonder, A. L., Hayman, S. R., Hobbs, M. A., Gonsalves, W. I., Warsame, R. M., Kourelis, et al
2019; 33 (3): 730–38
- **A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses** *LEUKEMIA & LYMPHOMA*

- McCarter, S. J., Vijayvargiya, P., Sidana, S., Nault, A. M., Lane, C. E., Lehman, J. S., Wilson, J. W., Parikh, S. A., Nowakowski, G. S., Al-Kali, A.
2019; 60 (2): 559–61
- **CAR T-cell therapy: is it prime time in myeloma?** *Blood advances*
Sidana, S. n., Shah, N. n.
2019; 3 (21): 3473–80
 - **Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?** *Hematology. American Society of Hematology. Education Program*
Sidana, S. n., Manasanch, E. n.
2019; 2019 (1): 142–47
 - **CAR T-cell therapy: is it prime time in myeloma?** *Hematology. American Society of Hematology. Education Program*
Sidana, S. n., Shah, N. n.
2019; 2019 (1): 260–65
 - **IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features.** *Leukemia*
Sidana, S. n., Larson, D. P., Greipp, P. T., He, R. n., McPhail, E. D., Dispenzieri, A. n., Murray, D. L., Dasari, S. n., Ansell, S. M., Muchtar, E. n., Gonsalves, W. I., Kourelis, T. V., Ramirez-Alvarado, et al
2019
 - **Should we measure clonal circulating plasma cells in light chain amyloidosis?** *Oncotarget*
Sidana, S., Kumar, S. K., Gonsalves, W. I.
2018; 9 (86): 35607–8
 - **59-Year-Old Man With Fatigue, Weight Loss, and Hepatomegaly** *MAYO CLINIC PROCEEDINGS*
Orme, J. J., Sidana, S., Gonsalves, W. I.
2018; 93 (10): 1525–29
 - **Reply to A. Piccardo et al, E. Hindie et al, MC Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al** *JOURNAL OF CLINICAL ONCOLOGY*
Molenaar, R. J., Sidana, S., Radivoyevitch, T., Gerds, A. T., Carraway, H. E., Kalaycio, M., Nazha, A., Adelstein, D. J., Nasr, C., Maciejewski, J. P., Majhail, N. S., Sekeres, M. A., Mukherjee, et al
2018; 36 (18): 1889–+
 - **Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer** *JOURNAL OF CLINICAL ONCOLOGY*
Molenaar, R. J., Sidana, S., Radivoyevitch, T., Advani, A. S., Gerds, A. T., Carraway, H. E., Angelini, D., Kalaycio, M., Nazha, A., Adelstein, D. J., Nasr, C., Maciejewski, J. P., Majhail, et al
2018; 36 (18): 1831–+
 - **Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis** *LEUKEMIA*
Sidana, S., Tandon, N., Dispenzieri, A., Gertz, M. A., Dingli, D., Jevremovic, D., Morice, W. G., Kapoor, P., Kourelis, T. V., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Leung, et al
2018; 32 (6): 1421–26
 - **The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response** *LEUKEMIA*
Sidana, S., Tandon, N., Dispenzieri, A., Gertz, M. A., Rajkumar, S., Kumar, S. K.
2018; 32 (5): 1243–46
 - **Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis** *BONE MARROW TRANSPLANTATION*
Sidana, S., Tandon, N., Gertz, M. A., Dispenzieri, A., Buadi, F. K., Lacy, M. Q., Dingli, D., Fonder, A. L., Hayman, S. R., Hobbs, M. A., Gonsalves, W. I., Hwa, Y., Kapoor, et al
2018; 53 (3): 326–33
 - **Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL)** *AMERICAN JOURNAL OF HEMATOLOGY*
Tandon, N., Sidana, S., Dispenzieri, A., Gertz, M. A., Lacy, M. Q., Dingli, D., Buadi, F. K., Fonder, A. L., Hayman, S. R., Hwa, Y., Hobbs, M. A., Kapoor, P., Gonsalves, et al
2018; 93 (1): 17–22
 - **Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine.** *Leukemia*

- Molenaar, R. J., Pleyer, C. n., Radivoyevitch, T. n., Sidana, S. n., Godley, A. n., Advani, A. S., Gerds, A. T., Carraway, H. E., Kalaycio, M. n., Nazha, A. n., Adelstein, D. J., Nasr, C. n., Angelini, et al
2018; 32 (4): 952–59
- **Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.** *Leukemia*
Sidana, S. n., Tandon, N. n., Dispenzieri, A. n., Gertz, M. A., Buadi, F. K., Lacy, M. Q., Dingli, D. n., Fonder, A. L., Hayman, S. R., Hobbs, M. A., Gonsalves, W. I., Hwa, Y. L., Kapoor, et al
2018; 32 (3): 729–35
 - **Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia** *AMERICAN JOURNAL OF HEMATOLOGY*
Sidana, S., Rajkumar, S., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Hayman, S. R., Dingli, D., Kapoor, P., Gonsalves, W. I., Go, R. S., Hwa, Y., Leung, et al
2017; 92 (7): 668–73
 - **Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis** *AMERICAN JOURNAL OF HEMATOLOGY*
Tandon, N., Sidana, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Buadi, F. K., Dingli, D., Fonder, A. L., Hobbs, M. A., Hayman, S. R., Gonsalves, W. I., Hwa, Y., Kapoor, et al
2017; 92 (6): 549–54
 - **Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis.** *PloS one*
Sidana, S., Narkhede, M., Elson, P., Hastings, D., Faiman, B., Valent, J., Samaras, C., Hamilton, K., Liu, H. K., Smith, M. R., Reu, F. J.
2017; 12 (3): e0172996
 - **Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis** *AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS*
Tandon, N., Sidana, S., Rajkumar, S., Dispenzieri, A., Gertz, M. A., Lacy, M. Q., Kyle, R. A., Buadi, F. K., Dingli, D., Hayman, S. R., Fonder, A. L., Hobbs, M. A., Gonsalves, et al
2017; 24 (3): 183–88
 - **Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival.** *Bone marrow transplantation*
Tandon, N. n., Muchtar, E. n., Sidana, S. n., Dispenzieri, A. n., Lacy, M. Q., Dingli, D. n., Buadi, F. K., Hayman, S. R., Chakraborty, R. n., Hogan, W. J., Gonsalves, W. n., Warsame, R. n., Kourelis, et al
2017; 52 (8): 1126–32
 - **Got zinc? An exfoliative rash in a parenteral nutrition-dependent patient.** *Journal of general internal medicine*
Sidana, S., Madanat, Y., Pile, J.
2015; 30 (4): 529-30
 - **Symptomatic and incidental venous thromboembolic disease are both associated with mortality in patients with prostate cancer.** *PloS one*
Chaturvedi, S., Sidana, S., Elson, P., Khorana, A. A., McCrae, K. R.
2014; 9 (8): e94048
 - **Prevalence of depression in students of a medical college in New Delhi: A cross-sectional study** *AUSTRALASIAN MEDICAL JOURNAL*
Sidana, S., Kishore, J., Ghosh, V., Gulati, D., Jiloha, R. C., Anand, T.
2012; 5 (5): 247–50